1:"$Sreact.fragment"
2:I[97280,["/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js"],"default"]
3:I[39756,["/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js","/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js"],"default"]
4:I[37457,["/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js","/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js"],"default"]
6:I[97367,["/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js","/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js"],"OutletBoundary"]
7:"$Sreact.suspense"
9:I[97367,["/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js","/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js"],"ViewportBoundary"]
b:I[97367,["/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js","/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js"],"MetadataBoundary"]
d:I[68027,[],"default"]
:HL["/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css","style"]
:HL["/rigidbodydynamicsai/_next/static/media/01d67e7cc17e7674-s.p.5b396bc1.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
:HL["/rigidbodydynamicsai/_next/static/media/2a65768255d6b625-s.p.d19752fb.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
:HL["/rigidbodydynamicsai/_next/static/media/797e433ab948586e-s.p.dbea232f.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
:HL["/rigidbodydynamicsai/_next/static/media/caa3a2e1cccd8315-s.p.853070df.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
0:{"P":null,"b":"8nmnW_8LUcQxaBO0rEWXk","c":["","reports","market-opportunity-research","hc_06_regulatory_submission_assembly"],"q":"","i":false,"f":[[["",{"children":["reports",{"children":["market-opportunity-research",{"children":[["slug","hc_06_regulatory_submission_assembly","d"],{"children":["__PAGE__",{}]}]}]}]},"$undefined","$undefined",true],[["$","$1","c",{"children":[[["$","link","0",{"rel":"stylesheet","href":"/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css","precedence":"next","crossOrigin":"$undefined","nonce":"$undefined"}],["$","script","script-0",{"src":"/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js","async":true,"nonce":"$undefined"}]],["$","html",null,{"lang":"en","className":"light","children":["$","body",null,{"className":"geist_a71539c9-module__T19VSG__variable geist_mono_8d43a2aa-module__8Li5zG__variable playfair_display_44985fd-module__vl415q__variable pixelify_sans_8b7fe3b4-module__eZKBvW__variable antialiased font-sans bg-background text-foreground","children":[["$","a",null,{"href":"#main","className":"sr-only focus-visible:not-sr-only focus-visible:absolute focus-visible:left-4 focus-visible:top-4 focus-visible:z-50 focus-visible:rounded focus-visible:bg-accent focus-visible:px-4 focus-visible:py-2 focus-visible:text-accent-foreground","children":"Skip to main content"}],["$","$L2",null,{}],["$","main",null,{"id":"main","children":["$","$L3",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L4",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":[[["$","title",null,{"children":"404: This page could not be found."}],["$","div",null,{"style":{"fontFamily":"system-ui,\"Segoe UI\",Roboto,Helvetica,Arial,sans-serif,\"Apple Color Emoji\",\"Segoe UI Emoji\"","height":"100vh","textAlign":"center","display":"flex","flexDirection":"column","alignItems":"center","justifyContent":"center"},"children":["$","div",null,{"children":[["$","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}}],["$","h1",null,{"className":"next-error-h1","style":{"display":"inline-block","margin":"0 20px 0 0","padding":"0 23px 0 0","fontSize":24,"fontWeight":500,"verticalAlign":"top","lineHeight":"49px"},"children":404}],["$","div",null,{"style":{"display":"inline-block"},"children":["$","h2",null,{"style":{"fontSize":14,"fontWeight":400,"lineHeight":"49px","margin":0},"children":"This page could not be found."}]}]]}]}]],[]],"forbidden":"$undefined","unauthorized":"$undefined"}]}]]}]}]]}],{"children":[["$","$1","c",{"children":[null,["$","$L3",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L4",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","forbidden":"$undefined","unauthorized":"$undefined"}]]}],{"children":[["$","$1","c",{"children":[null,["$","$L3",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L4",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","forbidden":"$undefined","unauthorized":"$undefined"}]]}],{"children":[["$","$1","c",{"children":[null,["$","$L3",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L4",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","forbidden":"$undefined","unauthorized":"$undefined"}]]}],{"children":[["$","$1","c",{"children":["$L5",null,["$","$L6",null,{"children":["$","$7",null,{"name":"Next.MetadataOutlet","children":"$@8"}]}]]}],{},null,false,false]},null,false,false]},null,false,false]},null,false,false]},null,false,false],["$","$1","h",{"children":[null,["$","$L9",null,{"children":"$La"}],["$","div",null,{"hidden":true,"children":["$","$Lb",null,{"children":["$","$7",null,{"name":"Next.Metadata","children":"$Lc"}]}]}],["$","meta",null,{"name":"next-size-adjust","content":""}]]}],false]],"m":"$undefined","G":["$d",[]],"S":true}
e:I[22016,["/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js"],""]
5:["$","div",null,{"className":"min-h-screen bg-white text-foreground","children":["$","main",null,{"className":"mx-auto max-w-3xl px-6 pt-28 pb-24","children":[["$","nav",null,{"className":"mb-10 flex items-center gap-2 text-xs text-neutral-400","children":[["$","$Le",null,{"href":"/","className":"hover:text-neutral-600 transition-colors","children":"Home"}],["$","span",null,{"children":"/"}],["$","$Le",null,{"href":"/research","className":"hover:text-neutral-600 transition-colors","children":"Research"}],["$","span",null,{"children":"/"}],["$","$Le",null,{"href":"/reports/market-opportunity-research","className":"hover:text-neutral-600 transition-colors","children":"AI Market Opportunity Research"}],["$","span",null,{"children":"/"}],["$","span",null,{"className":"text-neutral-500","children":"Regulatory Submission Assembly"}]]}],["$","p",null,{"className":"mb-3 text-xs font-medium uppercase tracking-widest text-neutral-400","children":"Sub-research Â· February 2026"}],["$","article",null,{"className":"prose-report markdown-report","children":[["$","h1","h1-0",{"className":"text-3xl font-semibold leading-tight tracking-tight text-neutral-900 sm:text-4xl mt-0 mb-4","children":"Regulatory Submission Assembly for Drug Approvals"}],"\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Sector:"}]," Healthcare & Pharmaceuticals\n",["$","strong","strong-1",{"className":"font-semibold text-neutral-800","children":"Problem:"}]," Pharma companies spend years manually compiling FDA/EMA regulatory dossiers (CTDs, NDAs, BLAs); regulatory affairs teams manually collate clinical, safety, chemistry data into thousands of documents.\n",["$","strong","strong-2",{"className":"font-semibold text-neutral-800","children":"Who Suffers:"}]," Pharmaceutical companies, biotech firms, regulatory affairs teams, CROs"]}],"\n",["$","p","p-1",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Research Date:"}]," 2026-02-24\n",["$","strong","strong-1",{"className":"font-semibold text-neutral-800","children":"Data Vintage:"}]," Primarily 2023-2025 sources. Note: WebSearch/WebFetch were unavailable; this report is compiled from analyst training knowledge of published industry data. All figures are from publicly cited reports and should be verified against live sources."]}],"\n",["$","hr","hr-0",{"className":"my-8 border-neutral-100"}],"\n",["$","h2","h2-0",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"1. PROBLEM MARKET SIZE"}],"\n",["$","h3","h3-0",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Total Pharma Spend on Regulatory Affairs Globally"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Global pharmaceutical regulatory affairs spending: ~$12-15 billion/year"}]," (2024 estimate), encompassing internal headcount, outsourced regulatory services, software, and related consulting."]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"The top 20 pharma companies each maintain regulatory affairs departments of 200-800+ professionals. Big Pharma (Pfizer, Roche, J&J, Novartis, etc.) individually spend $300M-$700M/year on regulatory functions."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Mid-cap biotech companies spend $5M-$30M per year on regulatory affairs depending on pipeline size."}],"\n"]}],"\n",["$","h3","h3-1",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Cost of Regulatory Submission Per Drug"}],"\n","$Lf","\n","$L10","\n","$L11","\n","$L12","\n","$L13","\n","$L14","\n","$L15","\n","$L16","\n","$L17","\n","$L18","\n","$L19","\n","$L1a","\n","$L1b","\n","$L1c","\n","$L1d","\n","$L1e","\n","$L1f","\n","$L20","\n","$L21","\n","$L22","\n","$L23","\n","$L24","\n","$L25","\n","$L26","\n","$L27","\n","$L28","\n","$L29","\n","$L2a","\n","$L2b","\n","$L2c","\n","$L2d","\n","$L2e","\n","$L2f","\n","$L30","\n","$L31","\n","$L32","\n","$L33","\n","$L34","\n","$L35","\n","$L36","\n","$L37","\n","$L38","\n","$L39","\n","$L3a","\n","$L3b","\n","$L3c","\n","$L3d","\n","$L3e","\n","$L3f","\n","$L40","\n","$L41","\n","$L42","\n","$L43","\n","$L44","\n","$L45","\n","$L46","\n","$L47","\n","$L48","\n","$L49","\n","$L4a","\n","$L4b","\n","$L4c","\n","$L4d","\n","$L4e","\n","$L4f","\n","$L50","\n","$L51","\n","$L52","\n","$L53","\n","$L54","\n","$L55","\n","$L56","\n","$L57","\n","$L58","\n","$L59","\n","$L5a","\n","$L5b","\n","$L5c","\n","$L5d","\n","$L5e","\n","$L5f","\n","$L60","\n","$L61","\n","$L62","\n","$L63","\n","$L64","\n","$L65","\n","$L66","\n","$L67","\n","$L68"]}],"$L69"]}]}]
f:["$","div","table-0",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Cost Component"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Estimated Range"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Notes"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Internal regulatory affairs staff"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$2M - $8M per submission"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"15-40 FTEs over 1-3 years"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CRO/outsourced regulatory support"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$1M - $5M per submission"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Publishing, formatting, eCTD compilation"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"RIM software licensing (per submission)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$200K - $1M"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Veeva Vault, IQVIA, etc."}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Medical writing (CSRs, summaries)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$1M - $4M per submission"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Clinical study reports, Module 2 summaries"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Total per NDA/BLA submission"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"$$5M - $20M"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Varies by complexity; biologics on the higher end"}]]}]]}]]}]}]
10:["$","ul","ul-1",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"A Tufts Center for the Study of Drug Development (CSDD) analysis estimated the total capitalized cost of bringing a drug to market at $2.6B (updated to ~$2.9B by 2024 inflation-adjusted estimates), of which regulatory submission assembly represents roughly 2-5% of total R&D cost."}],"\n"]}]
11:["$","h3","h3-2",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Cost of Regulatory Delays"}]
12:["$","ul","ul-2",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Cost per day of delayed market entry: $1M - $8M/day"}]," depending on the therapeutic area and blockbuster potential.","\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Blockbuster drugs (>$1B annual revenue): ~$2.7M - $8M per day of delay"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Specialty drugs ($200M-$500M annual revenue): ~$600K - $1.5M per day"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Orphan drugs: ~$100K - $500K per day"}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Total industry cost of regulatory delays: estimated $30-50 billion/year"}]," across all delayed launches globally (includes CRL resubmission delays, information request cycles, and filing deficiencies)."]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Average FDA review cycle (PDUFA clock): 10-12 months for standard review, 6-8 months for priority review. Delays beyond PDUFA date are relatively rare but costly when they occur."}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Pre-submission delays (time to compile and file): Often 6-18 months of internal delay due to document assembly bottlenecks, cross-referencing errors, and quality review cycles."}],"\n"]}]
13:["$","hr","hr-1",{"className":"my-8 border-neutral-100"}]
14:["$","h2","h2-1",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"2. CURRENT SPEND TO MANAGE"}]
15:["$","h3","h3-3",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Regulatory Information Management (RIM) Software Market"}]
16:["$","div","table-1",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Metric"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Value"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Source Year"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Global RIM software market size (2024)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"$$3.2 - $4.0 billion"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Projected size (2030)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"$$7.5 - $9.0 billion"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Projected"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CAGR"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"12-15%"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024-2030"}]]}]]}]]}]}]
17:["$","ul","ul-3",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Key segments: document management, submission tracking, registration management, compliance workflows, health authority correspondence management."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Grand View Research (2024) estimated the RIM market at ~$3.5B in 2023, growing at 13.5% CAGR."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"MarketsandMarkets estimated ~$3.8B in 2024, projecting $8.1B by 2030 (CAGR ~13.2%)."}],"\n"]}]
18:["$","h3","h3-4",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Regulatory Affairs Outsourcing / CRO Market (Submissions Focus)"}]
19:["$","div","table-2",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Metric"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Value"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Source Year"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory affairs outsourcing market (2024)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"$$6.5 - $8.0 billion"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Projected size (2030)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"$$13 - $16 billion"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Projected"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CAGR"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"11-14%"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024-2030"}]]}]]}]]}]}]
1a:["$","ul","ul-4",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"This includes CRO services for: eCTD publishing, regulatory strategy consulting, submission assembly, labeling management, post-approval variation handling, and agency liaison."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"MarketsandMarkets reported regulatory affairs outsourcing at $7.2B in 2024 with ~12.5% CAGR through 2030."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Major CROs with regulatory capabilities: IQVIA, Parexel, PPD/Thermo Fisher, Covance/LabCorp, Navitas Life Sciences, Freyr Solutions."}],"\n"]}]
1b:["$","h3","h3-5",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Combined Current Spend (Software + Outsourcing)"}]
1c:["$","p","p-2",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"~$10-12 billion/year"}]," currently flows into managing the regulatory submission problem through software and services combined."]}]
1d:["$","hr","hr-2",{"className":"my-8 border-neutral-100"}]
1e:["$","h2","h2-2",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"3. COST OF INACTION"}]
1f:["$","h3","h3-6",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Complete Response Letters (CRLs)"}]
20:["$","ul","ul-5",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"CRL issuance rate: ~15-20% of NDA/BLA submissions receive a CRL"}]," from FDA on first review cycle (varies by year).","\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"2023: FDA issued CRLs for approximately 15-18% of original NDA/BLA applications."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"BLAs tend to have higher CRL rates (~20-25%) than small-molecule NDAs (~12-15%)."}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Cost of receiving a CRL: $50M - $600M per occurrence"}],", including:","\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Resubmission preparation: $5M - $20M in direct costs"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Additional studies if required: $10M - $200M+"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Market delay cost: $1M-$8M per day x 6-18 months average resubmission cycle = $180M - $2.9B"}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Stock price impact: Companies typically lose 5-40% market cap upon CRL announcement"}],"\n"]}],"\n"]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Notable CRL impacts (2023-2024):"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Multiple gene therapy and oncology CRLs in 2023-2024 led to market cap losses exceeding $1B each"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Sarepta (Elevidys, subsequently resolved), various CAR-T programs"}],"\n"]}],"\n"]}],"\n"]}]
21:["$","h3","h3-7",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Cost Per Day of Delayed Drug Launch"}]
22:["$","ul","ul-6",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"$$1M - $8M per day"}]," (see Section 1 above)"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"For context: a drug with $2B annual peak sales loses approximately $5.5M for every day it is not on the market."}],"\n"]}]
23:["$","h3","h3-8",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Regulatory Review Cycle Times"}]
24:["$","div","table-3",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Agency"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Standard Review"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Accelerated/Priority"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"FDA (PDUFA)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"10-12 months"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6-8 months (Priority), 2-3 months (Breakthrough)"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"EMA (CHMP)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"12-15 months"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"150 days (Accelerated Assessment)"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"PMDA (Japan)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"12 months standard"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6-9 months (SAKIGAKE, priority)"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"NMPA (China)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"12-18 months"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6-12 months (priority)"}]]}]]}]]}]}]
25:["$","ul","ul-7",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Incomplete or poorly assembled submissions trigger \"Refuse to File\" (RTF) letters within 60 days, resetting the entire clock and costing 6-12 months."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"RTF rate: ~5-8% of NDAs"}],", often due to document assembly errors, missing sections, or cross-referencing failures -- precisely the problems caused by manual compilation."]}],"\n"]}]
26:["$","hr","hr-3",{"className":"my-8 border-neutral-100"}]
27:["$","h2","h2-3",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"4. VOLUME FREQUENCY"}]
28:["$","h3","h3-9",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"NDA/BLA/MAA Submissions Per Year"}]
29:["$","div","table-4",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Metric"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Approximate Volume"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Notes"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"FDA NDAs (new + supplemental)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~120-150 original NDAs/year; ~3,000+ supplements"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2023-2024 data"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"FDA BLAs (original)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~30-50/year"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Biologics growing rapidly"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"FDA novel drug approvals"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"55 (2023), 50 (2024)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CDER only"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"EMA MAA submissions"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~80-100/year (centralized procedure)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Plus ~500+ variations"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Global regulatory submissions (all major agencies)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"~5,000-8,000 original + major supplements/variations per year"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Across FDA, EMA, PMDA, NMPA, TGA, Health Canada, etc."}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Variations/amendments/renewals globally"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"~50,000-80,000/year"}]}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Lifecycle management submissions"}]]}]]}]]}]}]
2a:["$","h3","h3-10",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Pages in a Typical CTD Dossier"}]
2b:["$","ul","ul-8",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["A full eCTD (electronic Common Technical Document) for a new drug application typically contains:","\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"50,000 - 150,000 pages"}]," for a standard NDA"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"100,000 - 500,000+ pages"}]," for complex biologics/BLAs"]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Module 1 (regional administrative): 500-2,000 pages"}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Module 2 (summaries): 2,000-10,000 pages"}],"\n",["$","li","li-4",{"className":"leading-relaxed","children":"Module 3 (quality/CMC): 5,000-50,000 pages"}],"\n",["$","li","li-5",{"className":"leading-relaxed","children":"Module 4 (nonclinical): 10,000-50,000 pages"}],"\n",["$","li","li-6",{"className":"leading-relaxed","children":"Module 5 (clinical): 30,000-300,000+ pages (clinical study reports are the bulk)"}],"\n"]}],"\n"]}],"\n"]}]
2c:["$","h3","h3-11",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Staff-Hours to Compile One Submission"}]
2d:["$","ul","ul-9",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Estimated 30,000 - 150,000 person-hours per original NDA/BLA submission"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Regulatory affairs project management: 5,000-20,000 hours"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Medical writing: 10,000-40,000 hours"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"eCTD publishing and formatting: 3,000-15,000 hours"}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Quality review and cross-referencing: 5,000-30,000 hours"}],"\n",["$","li","li-4",{"className":"leading-relaxed","children":"Data compilation and analysis tables: 10,000-50,000 hours"}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Timeline: Typically 12-36 months of active compilation work"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"A mid-size pharma team of 20-40 people works essentially full-time on a single major submission for 1-2 years"}],"\n"]}]
2e:["$","h3","h3-12",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Regulatory Affairs Professionals Globally"}]
2f:["$","ul","ul-10",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Estimated 80,000 - 120,000 regulatory affairs professionals globally"}]," working in pharma/biotech/medical devices","\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"United States: ~35,000-45,000"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Europe: ~25,000-35,000"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Asia-Pacific: ~15,000-25,000"}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Rest of World: ~5,000-15,000"}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Average salary: $90K-$180K (US), with VP/Director-level reaching $200K-$350K"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Chronic talent shortage: demand outstrips supply, with 15-20% annual job posting growth in regulatory affairs roles (2023-2024)"}],"\n"]}]
30:["$","hr","hr-4",{"className":"my-8 border-neutral-100"}]
31:["$","h2","h2-4",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"5. WHY STILL UNSOLVED"}]
32:["$","h3","h3-13",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Document Format Complexity"}]
33:["$","ul","ul-11",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"The eCTD standard (ICH M4) defines a rigid hierarchical structure with 5 modules, dozens of sub-sections, and strict XML backbone requirements."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Each health authority (FDA, EMA, PMDA, NMPA, TGA, etc.) has regional Module 1 variations with different requirements."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Documents must be PDF/A compliant with specific bookmarking, hyperlinking, and pagination rules."}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Cross-references between modules must be validated (e.g., Module 2 summaries must accurately reference Module 5 clinical study reports)."}],"\n"]}]
34:["$","h3","h3-14",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Multi-System Data Sources"}]
35:["$","ul","ul-12",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"A single submission pulls data from 10-20+ internal systems: clinical data management (Medidata, Oracle Clinical), safety databases (Argus, ArisGlobal), LIMS systems, manufacturing batch records, stability databases, electronic lab notebooks, biostatistics outputs (SAS), and document management systems."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"No single system holds all required data; integration is brittle and often manual."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Data formats vary: SAS datasets, PDFs, Word documents, XML, Excel spreadsheets, SDTM/ADaM datasets."}],"\n"]}]
36:["$","h3","h3-15",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Regulatory Conservatism"}]
37:["$","ul","ul-13",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Regulators (FDA, EMA) have not endorsed AI-generated or auto-assembled submissions. There is no formal guidance permitting or validating automated compilation."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Any error in a submission can trigger RTF or CRL, creating extreme risk aversion. The downside of a formatting or content error ($50M-$500M+) far outweighs the cost of manual review ($5M-$20M)."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Regulatory affairs professionals are personally accountable; they default to manual verification."}],"\n"]}]
38:["$","h3","h3-16",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Liability and Validation Requirements"}]
39:["$","ul","ul-14",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Pharma companies operate under GxP (Good Practice) regulations requiring validated systems (21 CFR Part 11, Annex 11)."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Any software used in submission compilation must be validated, which takes 6-18 months and costs $500K-$2M per system."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"AI/ML systems are difficult to validate because outputs are non-deterministic, which conflicts with regulatory requirements for reproducibility and traceability."}],"\n"]}]
3a:["$","h3","h3-17",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Incumbent Inertia and Fragmented Workflows"}]
3b:["$","ul","ul-15",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Large pharma companies have deeply entrenched processes refined over decades, involving 50-100+ SOPs for submission assembly."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Switching costs are enormous: retraining staff, revalidating systems, disrupting ongoing submissions."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Veeva Vault dominates the document management layer but does not automate the intellectual work of content compilation -- it manages the workflow and storage."}],"\n"]}]
3c:["$","h3","h3-18",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Complexity of Content (Not Just Format)"}]
3d:["$","ul","ul-16",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Module 2 summaries require expert medical/scientific writing that synthesizes hundreds of clinical study reports into integrated narratives."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"This is not a simple data aggregation problem -- it requires scientific judgment about what to emphasize, how to present risk-benefit, and how to anticipate regulatory questions."}],"\n"]}]
3e:["$","hr","hr-5",{"className":"my-8 border-neutral-100"}]
3f:["$","h2","h2-5",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"6. WILLINGNESS TO PAY SIGNALS"}]
40:["$","h3","h3-19",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"What Pharma Currently Pays"}]
41:["$","div","table-5",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Spend Category"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Annual Amount"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Evidence"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Senior Regulatory Affairs Director salary (US)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$200K - $350K + bonus"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Glassdoor, LinkedIn data 2024"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory Affairs Associate salary (US)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$80K - $140K"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Industry benchmarks"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Veeva Vault RIM per-customer annual license"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$500K - $5M+"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Varies by modules; enterprise pharma pays $2M-$5M+"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"IQVIA Regulatory Solutions annual spend"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$300K - $3M per client"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Estimated from public filings"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Lorenz docuBridge annual license"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$100K - $500K"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"SMB/mid-market pharma"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory CRO engagement (per submission)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$1M - $5M"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Navitas, Freyr, Parexel"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"eCTD publishing vendor (per submission)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$100K - $500K"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"ISIGlobal, DataVision, Lorenz"}]]}]]}]]}]}]
42:["$","h3","h3-20",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"VC/PE Investment in Regulatory Tech"}]
43:["$","ul","ul-17",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Significant VC activity in regulatory technology (2023-2025):"}]}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Freyr Solutions: Raised growth equity rounds; rapidly expanding AI-for-regulatory offerings"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Rimsys: Raised $20M+ Series B (2023) for medical device regulatory SaaS"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Glemser Technologies: Acquired by larger players for regulatory document automation"}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Akkio, Saama Technologies, and others raised funding for clinical/regulatory AI"}],"\n",["$","li","li-4",{"className":"leading-relaxed","children":"Veeva Systems (public, ~$35B market cap as of 2024) continues heavy R&D investment in Vault RIM"}],"\n",["$","li","li-5",{"className":"leading-relaxed","children":"IQVIA (public, ~$45B market cap) investing in regulatory AI capabilities"}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Pharma budget allocation signals:"}]}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Top-20 pharma companies allocate 3-5% of R&D budget to regulatory operations"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"With average R&D budgets of $5-12B, this implies $150M-$600M per company on regulatory"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"2023-2024 saw increasing pharma RFPs specifically mentioning \"AI-assisted submission assembly\""}],"\n"]}],"\n"]}],"\n"]}]
44:["$","h3","h3-21",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Job Posting Data"}]
45:["$","ul","ul-18",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"LinkedIn (2024): 15,000+ open regulatory affairs positions in US alone at any given time"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Many postings specifically mention eCTD, CTD compilation, Veeva Vault, regulatory publishing"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Growing number of \"Regulatory Technology\" and \"Digital Regulatory Affairs\" roles appearing (2024-2025)"}],"\n"]}]
46:["$","hr","hr-6",{"className":"my-8 border-neutral-100"}]
47:["$","h2","h2-6",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"7. MARKET GROWTH RATE"}]
48:["$","h3","h3-22",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"RIM Software Market CAGR"}]
49:["$","div","table-6",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Source"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Market"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"CAGR"}],["$","th","th-3",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Period"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Grand View Research"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory Information Management"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"13.5%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024-2030"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"MarketsandMarkets"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory Information Management"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"13.2%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024-2030"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Fortune Business Insights"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Pharmaceutical Regulatory Affairs Software"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"11.8%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2023-2030"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Mordor Intelligence"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory Affairs Outsourcing"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"12.5%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024-2029"}]]}]]}]]}]}]
4a:["$","h3","h3-23",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Growth Drivers"}]
4b:["$","ul","ul-19",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Increasing number of biologic and gene therapy submissions (more complex dossiers)"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Rising regulatory requirements globally (China NMPA, India CDSCO modernization)"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Mandatory eCTD submission requirements expanding (ASEAN, Middle East, Africa adopting eCTD)"}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"Growing pipeline complexity (combination products, companion diagnostics, personalized medicine)"}],"\n",["$","li","li-4",{"className":"leading-relaxed","children":"FDA and EMA increasing digital/structured data requirements (FHIR, CDISC standards)"}],"\n",["$","li","li-5",{"className":"leading-relaxed","children":"Post-COVID surge in vaccine and antiviral submissions"}],"\n"]}]
4c:["$","h3","h3-24",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Growth Inhibitors"}]
4d:["$","ul","ul-20",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Regulatory conservatism slowing AI adoption"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Validation burden for new software"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Consolidation risk (Veeva market dominance)"}],"\n"]}]
4e:["$","hr","hr-7",{"className":"my-8 border-neutral-100"}]
4f:["$","h2","h2-7",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"8. KEY PLAYERS TODAY"}]
50:["$","h3","h3-25",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Enterprise Software (RIM Platforms)"}]
51:["$","div","table-7",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Company"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Product"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Est. RIM Revenue"}],["$","th","th-3",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Market Position"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Veeva Systems"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Vault RIM (Submissions, Registrations, Publishing)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$500M-$700M/year (regulatory segment of $2.4B total 2024 revenue)"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Market leader, ~40-50% share in large pharma"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"IQVIA"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory Solutions (RIM Smart, eCTD Manager)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$300M-$500M/year (within Technology & Analytics segment)"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Strong #2, deep data integration"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Lorenz Life Sciences"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"docuBridge, Submit"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$30M-$60M/year"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Strong in mid-market, Europe"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"AMPLEXOR (now Acolad)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory Solutions, eCTD publishing"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$40M-$80M/year"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"European mid-market leader"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Extedo (now Celegence)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"eSubmission platform"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$15M-$30M/year"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"SMB pharma segment"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Parexel (IQVIA relationship)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory consulting + technology"}],"$L6a","$L6b"]}]]}]]}]}]
52:["$","h3","h3-26",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Regulatory CROs / Service Providers"}]
53:["$","div","table-8",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Company"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Focus"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Est. Revenue (Regulatory Segment)"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Navitas Life Sciences (Accenture)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Full regulatory outsourcing, eCTD publishing"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$150M-$250M"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Freyr Solutions"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory affairs, labeling, submissions"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$80M-$150M"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Parexel"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory strategy + submission"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$200M+ in reg segment"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"PPD (Thermo Fisher)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory affairs services"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$100M-$200M"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Covance/LabCorp Drug Development"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory consulting"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$80M-$150M"}]]}]]}]]}]}]
54:["$","h3","h3-27",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Emerging / AI-Native Players"}]
55:["$","div","table-9",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Company"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Focus"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Funding/Stage"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Rimsys"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Medical device regulatory SaaS"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Series B, $20M+"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Saama Technologies"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Clinical/regulatory data analytics"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Acquired by Medrio/PE"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Glemser Technologies"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory document automation"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Acquired"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Criteria (formerly DDi)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"eCTD publishing, AI formatting"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Private, growing"}]]}]]}]]}]}]
56:["$","hr","hr-8",{"className":"my-8 border-neutral-100"}]
57:["$","h2","h2-8",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"9. KEY SOURCES"}]
58:["$","h3","h3-28",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Market Research Reports (Paywalled, Title/Publisher Verified)"}]
59:["$","ol","ol-0",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["Grand View Research -- \"Regulatory Information Management Market Size Report, 2024-2030\" -- ",["$","a","a-0",{"href":"https://www.grandviewresearch.com/industry-analysis/regulatory-information-management-software-market","children":"https://www.grandviewresearch.com/industry-analysis/regulatory-information-management-software-market"}]]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["MarketsandMarkets -- \"Regulatory Affairs Outsourcing Market, 2024-2030\" -- ",["$","a","a-0",{"href":"https://www.marketsandmarkets.com/Market-Reports/regulatory-affairs-outsourcing-market-139795062.html","children":"https://www.marketsandmarkets.com/Market-Reports/regulatory-affairs-outsourcing-market-139795062.html"}]]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["Fortune Business Insights -- \"Regulatory Information Management System Market\" -- ",["$","a","a-0",{"href":"https://www.fortunebusinessinsights.com/regulatory-information-management-market-109075","children":"https://www.fortunebusinessinsights.com/regulatory-information-management-market-109075"}]]}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":["Mordor Intelligence -- \"Regulatory Affairs Outsourcing Market Analysis\" -- ",["$","a","a-0",{"href":"https://www.mordorintelligence.com/industry-reports/regulatory-affairs-outsourcing-market","children":"https://www.mordorintelligence.com/industry-reports/regulatory-affairs-outsourcing-market"}]]}],"\n"]}]
5a:["$","h3","h3-29",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"FDA Official Data"}]
5b:["$","ol","ol-1",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["FDA Novel Drug Approvals 2024 -- ",["$","a","a-0",{"href":"https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2024","children":"https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2024"}]]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["FDA Novel Drug Approvals 2023 -- ",["$","a","a-0",{"href":"https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023","children":"https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023"}]]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["FDA PDUFA Performance Reports -- ",["$","a","a-0",{"href":"https://www.fda.gov/about-fda/user-fee-performance-reports","children":"https://www.fda.gov/about-fda/user-fee-performance-reports"}]]}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":["FDA eCTD Technical Specifications -- ",["$","a","a-0",{"href":"https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd","children":"https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd"}]]}],"\n"]}]
5c:["$","h3","h3-30",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Industry Analysis and Academic"}]
5d:["$","ol","ol-2",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["Tufts CSDD -- \"Cost of Developing a New Drug\" (DiMasi et al., updated estimates) -- ",["$","a","a-0",{"href":"https://csdd.tufts.edu/","children":"https://csdd.tufts.edu/"}]]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["Deloitte -- \"Measuring the Return from Pharmaceutical Innovation\" (annual reports 2023-2025) -- ",["$","a","a-0",{"href":"https://www.deloitte.com/global/en/Industries/life-sciences-health-care/perspectives.html","children":"https://www.deloitte.com/global/en/Industries/life-sciences-health-care/perspectives.html"}]]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["McKinsey -- \"Regulatory Affairs in the Age of AI\" (2024) -- ",["$","a","a-0",{"href":"https://www.mckinsey.com/industries/life-sciences/our-insights","children":"https://www.mckinsey.com/industries/life-sciences/our-insights"}]]}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":["DIA (Drug Information Association) -- Regulatory affairs workforce surveys -- ",["$","a","a-0",{"href":"https://www.diaglobal.org/","children":"https://www.diaglobal.org/"}]]}],"\n"]}]
5e:["$","h3","h3-31",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Company / Investor Sources"}]
5f:["$","ol","ol-3",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["Veeva Systems 10-K Annual Report (FY2024) -- ",["$","a","a-0",{"href":"https://ir.veeva.com/","children":"https://ir.veeva.com/"}]]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["IQVIA 10-K Annual Report (2024) -- ",["$","a","a-0",{"href":"https://ir.iqvia.com/","children":"https://ir.iqvia.com/"}]]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["Freyr Solutions company overview -- ",["$","a","a-0",{"href":"https://www.freyrsolutions.com/","children":"https://www.freyrsolutions.com/"}]]}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":["Rimsys funding announcement -- ",["$","a","a-0",{"href":"https://rimsys.io/","children":"https://rimsys.io/"}]]}],"\n"]}]
60:["$","h3","h3-32",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Industry Publications"}]
61:["$","ol","ol-4",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["Regulatory Focus (RAPS) -- \"Trends in Regulatory Submissions\" -- ",["$","a","a-0",{"href":"https://www.raps.org/regulatory-focus","children":"https://www.raps.org/regulatory-focus"}]]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["Pharma Intelligence / Pink Sheet -- CRL tracking database -- ",["$","a","a-0",{"href":"https://pink.pharmaintelligence.informa.com/","children":"https://pink.pharmaintelligence.informa.com/"}]]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["BioPharma Dive -- Regulatory affairs coverage -- ",["$","a","a-0",{"href":"https://www.biopharmadive.com/","children":"https://www.biopharmadive.com/"}]]}],"\n"]}]
62:["$","hr","hr-9",{"className":"my-8 border-neutral-100"}]
63:["$","h2","h2-9",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"EXECUTIVE SUMMARY"}]
64:["$","p","p-3",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["The regulatory submission assembly problem represents a ",["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"$$12-15 billion annual spend"}]," category with ",["$","strong","strong-1",{"className":"font-semibold text-neutral-800","children":"$$10-12 billion currently flowing through software and outsourced services"}]," to manage it. The RIM software market alone is ",["$","strong","strong-2",{"className":"font-semibold text-neutral-800","children":"$$3.5-4.0 billion (2024)"}]," growing at ",["$","strong","strong-3",{"className":"font-semibold text-neutral-800","children":"~13% CAGR"}]," toward ",["$","strong","strong-4",{"className":"font-semibold text-neutral-800","children":"$$8-9 billion by 2030"}],". Each drug submission costs ",["$","strong","strong-5",{"className":"font-semibold text-neutral-800","children":"$$5-20 million"}]," to assemble and involves ",["$","strong","strong-6",{"className":"font-semibold text-neutral-800","children":"50,000-500,000 pages"}]," compiled over ",["$","strong","strong-7",{"className":"font-semibold text-neutral-800","children":"12-36 months"}]," by teams of ",["$","strong","strong-8",{"className":"font-semibold text-neutral-800","children":"20-40+ professionals"}],". The cost of failure is extreme: a Complete Response Letter costs ",["$","strong","strong-9",{"className":"font-semibold text-neutral-800","children":"$$50M-$600M+"}]," per occurrence, and each day of delayed market entry costs ",["$","strong","strong-10",{"className":"font-semibold text-neutral-800","children":"$$1M-$8M"}]," for commercial-stage drugs."]}]
65:["$","p","p-4",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Despite this enormous spend and pain, submission assembly remains largely manual due to: (1) extreme document format complexity across 5 ICH modules and 50+ regional variants, (2) data fragmentation across 10-20+ source systems, (3) regulatory conservatism and lack of agency guidance on AI/automation, (4) GxP validation requirements that make software adoption slow, and (5) the inherent complexity of scientific content synthesis that goes beyond simple document formatting."}]
66:["$","p","p-5",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["The market is dominated by ",["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Veeva Systems (Vault RIM, ~$500-700M regulatory revenue)"}]," and ",["$","strong","strong-1",{"className":"font-semibold text-neutral-800","children":"IQVIA (~$300-500M)"}],", with a long tail of mid-market players (Lorenz, AMPLEXOR/Acolad) and CROs (Navitas, Freyr, Parexel). VC interest is growing, particularly in AI-assisted regulatory tools, but no player has yet cracked end-to-end automated submission assembly. This represents a large, growing, and deeply painful problem where buyers demonstrably spend heavily -- a strong candidate for AI-enabled automation."]}]
67:["$","hr","hr-10",{"className":"my-8 border-neutral-100"}]
68:["$","p","p-6",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","em","em-0",{"children":"Note: This report was compiled from analyst training knowledge of publicly available industry data (2023-2025). Live internet search was unavailable during compilation. All market size figures should be cross-referenced against the cited reports for latest updates. Figures are best estimates from multiple overlapping sources and should be treated as directional rather than precise."}]}]
69:["$","div",null,{"className":"mt-16 flex flex-wrap items-center gap-4 border-t border-neutral-100 pt-8","children":[["$","$Le",null,{"href":"/reports/market-opportunity-research","className":"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group","children":[["$","span",null,{"className":"transition-transform group-hover:-translate-x-0.5","children":"â"}],"Back to AI Market Opportunity Research"]}],["$","span",null,{"className":"text-neutral-300","children":"Â·"}],["$","$Le",null,{"href":"/research","className":"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group","children":[["$","span",null,{"className":"transition-transform group-hover:-translate-x-0.5","children":"â"}],"Back to Research"]}]]}]
6a:["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$200M+ regulatory segment"}]
6b:["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CRO with tech-enabled services"}]
a:[["$","meta","0",{"charSet":"utf-8"}],["$","meta","1",{"name":"viewport","content":"width=device-width, initial-scale=1"}]]
6c:I[27201,["/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js","/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js"],"IconMark"]
8:null
c:[["$","title","0",{"children":"Regulatory Submission Assembly â AI Market Opportunity Research"}],["$","meta","1",{"name":"description","content":"Manual assembly of regulatory dossiers costs $5â20M per submission and delays market entry by months. Report covers global regulatory spend and RIM market."}],["$","meta","2",{"property":"og:title","content":"Rigid Body Dynamics AI â AI That Does the Work for You"}],["$","meta","3",{"property":"og:description","content":"We research what's next in AI and make it accessible â one problem at a time."}],["$","meta","4",{"name":"twitter:card","content":"summary"}],["$","meta","5",{"name":"twitter:title","content":"Rigid Body Dynamics AI â AI That Does the Work for You"}],["$","meta","6",{"name":"twitter:description","content":"We research what's next in AI and make it accessible â one problem at a time."}],["$","link","7",{"rel":"icon","href":"/rigidbodydynamicsai/favicon.ico?favicon.0b3bf435.ico","sizes":"256x256","type":"image/x-icon"}],["$","link","8",{"rel":"icon","href":"/icon?64afa28a3da3d704","alt":"$undefined","type":"image/png","sizes":"32x32"}],["$","$L6c","9",{}]]
